전이성 전립선암 환자에서 내분비요법 후 예후에 영향을 미치는 인자 = The Factors Affecting Prognosis in Patients with Metastatic Prostate Cancer after Hormonal Therapy

다국어 초록 (Multilingual Abstract)

Purpose: To assess the prognostic value of clinical factors in patients with metastatic prostate cancer after androgen deprivation treatment.
Materials and Methods: Fifty-three patients with metastatic prostate cancer treated with androgen deprivation therapy were included in this analysis. We analyzed a variety of possible prognostic factors, such as age, pretreatment prostate specific antigen(PSA), Gleason score, extent of metastasis, PSA at 3 and 6 months, nadir PSA, hemoglobin, performance status using Kaplan-Meier's survival curve and Cox proportional hazard model.
Results: Age, pre-treatment PSA, PSA at 3 months, antiandrogen, nadir PSA, Gleason score, and hemoglobin did not influence survival. PSA at 6 months, extent of metastasis and performance status proved to have prognostic value in univariate analysis. However, multivariate analysis demonstrated that PSA at 6 months and extent of metastasis were significantly correlated with survival rate, but performance status was not.
Conclusions: The results of present study suggest that PSA at 6 months and extent of metastasis are significant prognostic indicators for survival in patients with metastatic prostate cancer treated with androgen deprivation therapy. Korean J Urol 2004;45:24-28)

참고문헌 (Reference)

1 "한국중앙암등록사업연례보고서 2001." 10-1, 2003

2 "전이성 전립선암 환자의 예후인자에 대한 분석." 41 : 205-211, 2000

3 "et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988" 195-202

4 "et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989" 419-24,

5 "Venner PM. Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. J Urol 1991" 372-6,

6 "Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989" 1139-42,

7 "The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate." 78 : 426-431, 1996

8 "Stein GJ. Cancer of the prostate. Do younger men have a poorer survival rate" 391-6, brjurol1984

9 "Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy." 168 : 1423-1426, 2002

10 "Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer." 168 : 995-1000, 2002

11 "Prognostic factors in patients with prostate cancer refractory to endocrine therapy univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase." 27 : 258-262, 1997

12 "PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients." 65 : 63-71, 1997

13 "Natural history of cancer of the prostate. J Urol 1987" 469-74,

14 "Importance of serum hemoglobin in hormone refractory prostate cancer." 8 : 1049-1053, 2002

15 "Gleason score predicts androgen independent progression after androgen deprivation therapy." 42 : 12-17, 2002

16 "Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer." 569-574, 1997

17 "Complete androgen blockade for prostate cancer: what went wrong?" 164 : 3-9, 2000

18 "Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979" 159-63,

19 "Changes in biomarker expression in the development of prostatic adenocarcinoma." 72 : 86-95, 1997

20 "Carducci MA. Chemotherapy for hormone- resistant prostate cancer." 3209-3226, 2002

21 "Bottaccini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992" 956-61,

22 "Andriole GL. Serum PSA after antiandrogen therapy. Urol Clin North Am 1993" 749-56,